Apeloa Pharmaceutical Co Ltd (000739) — Cash Flow-to-Debt Ratio
Apeloa Pharmaceutical Co Ltd (000739) has a Cash Flow-to-Debt Ratio of 0.07x as of December 2025, meaning its operating cash flow of CN¥446.18 Million could theoretically repay 0% of its total liabilities (CN¥5.97 Billion) in one year. See free cash flow generation of Apeloa Pharmaceutical Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Apeloa Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Apeloa Pharmaceutical Co Ltd across 28 annual periods. Also explore net asset growth rate of Apeloa Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Apeloa Pharmaceutical Co Ltd (1998–2025)
Year-by-year debt coverage analysis for Apeloa Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see Apeloa Pharmaceutical Co Ltd market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.21x | CN¥1.23 Billion | CN¥5.97 Billion | ▲ +1.9% |
| 2024 | 0.20x | CN¥1.21 Billion | CN¥5.98 Billion | ▲ +28.1% |
| 2023 | 0.16x | CN¥1.03 Billion | CN¥6.54 Billion | ▼ -22.6% |
| 2022 | 0.20x | CN¥1.33 Billion | CN¥6.50 Billion | ▲ +32.8% |
| 2021 | 0.15x | CN¥611.75 Million | CN¥3.98 Billion | ▼ -55.0% |
| 2020 | 0.34x | CN¥1.06 Billion | CN¥3.10 Billion | ▼ -30.9% |
| 2019 | 0.49x | CN¥1.36 Billion | CN¥2.75 Billion | ▲ +42.7% |
| 2018 | 0.35x | CN¥832.69 Million | CN¥2.41 Billion | ▲ +335.6% |
| 2017 | 0.08x | CN¥209.80 Million | CN¥2.64 Billion | ▲ +32.2% |
| 2016 | 0.06x | CN¥180.42 Million | CN¥3.00 Billion | ▼ -59.4% |
| 2015 | 0.15x | CN¥441.16 Million | CN¥2.98 Billion | ▼ -48.1% |
| 2014 | 0.29x | CN¥786.64 Million | CN¥2.76 Billion | ▲ +320.3% |
| 2013 | 0.07x | CN¥190.45 Million | CN¥2.80 Billion | ▼ -44.6% |
| 2012 | 0.12x | CN¥335.90 Million | CN¥2.74 Billion | ▼ -27.5% |
| 2011 | 0.17x | CN¥404.62 Million | CN¥2.40 Billion | ▲ +44.6% |
| 2010 | 0.12x | CN¥121.05 Million | CN¥1.04 Billion | ▼ -46.4% |
| 2009 | 0.22x | CN¥208.30 Million | CN¥954.91 Million | ▲ +124.4% |
| 2008 | 0.10x | CN¥94.57 Million | CN¥973.00 Million | ▼ -51.8% |
| 2007 | 0.20x | CN¥174.20 Million | CN¥864.02 Million | ▲ +4.8% |
| 2006 | 0.19x | CN¥159.43 Million | CN¥828.68 Million | ▲ +61.3% |
| 2005 | 0.12x | CN¥87.40 Million | CN¥732.94 Million | ▲ +86.4% |
| 2004 | 0.06x | CN¥47.54 Million | CN¥743.40 Million | ▼ -67.6% |
| 2003 | 0.20x | CN¥105.36 Million | CN¥534.24 Million | ▲ +2672.0% |
| 2002 | 0.01x | CN¥2.81 Million | CN¥395.59 Million | ▲ +509.1% |
| 2001 | 0.00x | CN¥-569.79K | CN¥327.67 Million | ▼ -104.4% |
| 2000 | 0.04x | CN¥7.08 Million | CN¥177.79 Million | ▲ +141.2% |
| 1999 | -0.10x | CN¥-20.52 Million | CN¥212.40 Million | ▼ -172.9% |
| 1998 | 0.13x | CN¥30.10 Million | CN¥227.17 Million | — |